NASDAQ · BIVI
BioVie Inc.
$1.38-$0.08 (-5.48%)
BioVie Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.59% below the high.
Loading market information…
NASDAQ · GNPX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Genprex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Genprex, Inc.’s next earnings report is currently expected on Dec 2, 2026, with estimated earnings per share of -$6,160.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Genprex, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q3 2024 | Nov 13, 2024 | -$1,351.65-8.85% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.38-$0.08 (-5.48%)
BioVie Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.59% below the high.
$1.63+$0.03 (+1.61%)
InMed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.26% below the high.
$0.19-$0.00 (-1.53%)
Theriva Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.99% below the high.
$1.09-$0.01 (-0.91%)
Chemomab Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 66.25% below the high.
$4.77+$0.26 (+5.76%)
CNS Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.74% below the high.
$2.04-$0.06 (-2.86%)
Jaguar Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.81% below the high.
$2.90-$0.03 (-0.86%)
Liminatus Pharma, Inc. Class A Common Stock’s quoted price sits in the lower half of its reported 52-week range, 97.95% below the high.
$1.57-$0.06 (-3.38%)
GRI Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.55% below the high.
